Status:
COMPLETED
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
World Health Organization
HealthNet TPO
Conditions:
Malaria
Falciparum Malaria
Eligibility:
All Genders
5-70 years
Phase:
PHASE3
Brief Summary
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To ...
Detailed Description
The incidence of falciparum malaria in Pakistan has risen 6-fold over the last 15 years and chloroquine resistance is prevalent in every malarious area examined. Chloroquine's position as first line t...
Eligibility Criteria
Inclusion
- adults or children \> 5 yrs
- weight \> 5 kg
- monoinfection with P. falciparum or P. vivax
- history of recent fever
- consent from patient or parent.
Exclusion
- patients with signs of severe malaria.
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00158548
Start Date
June 1 2001
End Date
December 1 2004
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HealthNet International
Peshawar, Pakistan